Pamidronate: all 28 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Effect of Local Pamidronate in Preventing Bone Loss After Total Hip ArthroplastyNot yet recruitingNCT00548288Phase 1
• Prevention of Bone Loss After Pediatric Hematopoietic Cell TransplantationCompletedNCT02074631Phase 2Results posted
• Prevention of Post Operative Bone Loss in ChildrenCompletedNCT00655681Not applicableResults posted
• Bisphosphonate Therapy for Osteogenesis ImperfectaCompletedNCT00159419Phase 4Results posted
• Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and ThalidomideCompletedNCT00083382Phase 2Results posted
• Pamidronate to Treat Osteogenesis Imperfecta in ChildrenCompletedNCT00005901Phase 3Results posted
• 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone MetastasesCompletedNCT02721433Phase 4
• Efficacy of Bisphosphonates in Patients With Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) SyndromeCompletedNCT02544659Phase 1
• Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic ProgressionStatus unknownNCT02313727Phase 4
• Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone DiseaseWithdrawnNCT02101164Phase 4
• The Use of Bisphosphonates in the Treatment of Avascular Necrosis of the Femoral HeadTerminatedNCT02007915Not applicable
• The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast CancerCompletedNCT01907880Phase 4
• Efficiency and Safety Study of Pamidronate in Inflammatory Back Pain Due to Degenerative Disk DiseaseStatus unknownNCT01799616Phase 2
• Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week TrialCompletedNCT01718951Phase 4
• A Pilot Trial of IV Pamidronate for Low Back PainCompletedNCT01210599Phase 1/2
• Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast CancerTerminatedNCT01067989Phase 2
• A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.CompletedNCT00738257Phase 4
• Efficacy of Pamidronate in the Treatment of Bone Loss Associated With Liver TransplantCompletedNCT00657852Phase 4
• Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone PainCompletedNCT00482378Phase 1/2
• Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/MonthCompletedNCT00376883Phase 3
• Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart TransplantationCompletedNCT00302627Not applicable
• Study of Pamidronate for the Prevention of Heterotopic OssificationWithdrawnNCT00262392Not applicable
• Pamidronate Administration in Breast Cancer Patients With Bone MetastasesCompletedNCT00128297Phase 4
• Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple MyelomaCompletedNCT00124605Phase 1
• Osteopenia and Renal Osteodystrophy: Evaluation and ManagementCompletedNCT00108394Phase 4
• A Pilot Trial of Intravenous (IV) Pamidronate for Low Back PainStatus unknownNCT00101790Phase 1
• Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and ThalidomideCompletedNCT00083408Phase 2
• Prevention of Steroid-Induced Osteoporosis in ChildrenTerminatedNCT00022841Phase 1/2

← Pamidronate overview